Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
My Lists

Aduro BioTech  (Stock symbol: ADRO )

626 Bancroft Way, 3C
Berkeley, CA 94710
Website Company Summary Management Team

Outside board: (May no longer be on the board) William M. Greenman (Cerus Chief Business Officer) Frank McCormick (University of California, San Francisco Associate Dean) Gerald Chan (Morningside co-Founder) Stephanie O’Brien (Morningside Ventures) Stephen A. Sherwin (Cell Genesys) Ross Haghighat (Triton Systems Founding CEO)
Advisory board: Drew M. Pardoll (Johns Hopkins University School of Medicine Former Professor)
Former outside board: Roy Skogstrom (Oncologic Former President/CEO);  Walter H. Moos (MitoKor CEO/Chairman) Michael F. Powell (Sofinnova Investments Former General Partner) William Gibson (CR Ventures);  Donald Macleod (Wireless SVP);  Christopher Ray (Natural Gas Partners Principal);  Winston Salser (UCLA Professor of Molecular Genetics);  Dale Stevens (Grasswood Partners President)

Business description: Aduro Biotech, Inc. is a private, clinical-stage immuno-oncology company focused on the development of its live, attenuated, double-deleted (LADD) Listeria monocytogenes and cyclic dinucleotide (CDN) technology platforms to initiate powerful innate immune responses and drive targeted, durable adaptive immune responses against cancer. Aduro has received Breakthrough Therapy designation from the FDA for its lead immuno-oncology regimen, CRS-207 and GVAX Pancreas, in pancreatic cancer. The company is evaluating CRS-207 and GVAX Pancreas in the ongoing Phase 2b ECLIPSE clinical trial and has additional ongoing clinical trials with its LADD product candidates in mesothelioma and glioblastoma. The company is also developing clinical candidates using synthetic small molecule CDNs that are designed to activate the intracellular STING receptor.
Partners include: Novartis ;  Baylor College of Medicine;  Lawrence Berkeley National Labs

Rounds: 4
Recent Fundings: Jan 2015   Jun 2014
Capital raised: 143.0M
Last Round: 51.4M
Ownership: Public   Ipo Filing
Stock Symbol: ADRO
VCs include: Sofinnova Investments OrbiMed ;  Morningside Ventures;  Jennison Associates Foresite Capital ;  Clough Capital Partners ;  Janus Capital

Last Tweets


Last Mentions

Record updated: Jan 2018
Sector: Biotech
Headcount: 101-150 as of Feb 2019
Rounds: 4
Recent Fundings: Jan 2015   Jun 2014
Capital Raised: 143.0M
Last Round: 51.4M
Ownership: Public   Ipo Filing
Stock Symbol: ADRO